search

Arrowhead Pharmaceuticals Inc (ARWR)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
Sep 16, 2026

ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction

Shares of Arrowhead Pharmaceuticals (ARWR) experienced their worst day in over a year, falling more than 10% despite releasing positive early-stage human trial data for its experimental cholesterol drug, ARO-DIMER-PA. The drug showed significant reductions in "bad" cholesterol and triglycerides, but analysts suggest the selloff could be a "sell the news" reaction, as the stock had previously run up in anticipation of the catalyst. Retail investors, however, appear to be buying the dip, with sentiment shifting from bearish to bullish on platforms like Stocktwits.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish